Log in

Relevant bibliographies by topics / COVID-19 outcomes / Journal articles

Journal articles on the topic 'COVID-19 outcomes'

To see the other types of publications on this topic, follow the link: COVID-19 outcomes.

Author: Grafiati

Published: 10 December 2022

Last updated: 28 January 2023

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'COVID-19 outcomes.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Karabulut, Gokhan, Klaus F. Zimmermann, Mehmet Huseyin Bilgin, and Asli Cansin Doker. "Democracy and COVID-19 outcomes." Economics Letters 203 (June 2021): 109840. http://dx.doi.org/10.1016/j.econlet.2021.109840.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Ilardi, Alfonso. "COVID-19: Gender and Outcomes." Encyclopedia 2, no. 2 (April 22, 2022): 864–72. http://dx.doi.org/10.3390/encyclopedia2020056.

Full text

Abstract:

The existence of differences in susceptibility to SARS-CoV-2 infection between males and females in both incidence and outcomes is well documented in the scientific literature. These differences, which are still underestimated, may have important implications in terms of prevention, diagnosis, and treatment of COVID-19, with significant prognostic consequences. The greater severity of the infection observed in males, even more so if they are elderly, would seem, according to current knowledge, to be due to multiple influences: immunological and endocrinological, but also genetic and behavioral.

APA, Harvard, Vancouver, ISO, and other styles

3

Parrotta, Erica, Ilya Kister, Leigh Charvet, Carrie Sammarco, Valerie Saha, Robert Erik Charlson, Jonathan Howard, et al. "COVID-19 outcomes in MS." Neurology - Neuroimmunology Neuroinflammation 7, no. 5 (July 9, 2020): e835. http://dx.doi.org/10.1212/nxi.0000000000000835.

Full text

Abstract:

ObjectiveTo report outcomes on patients with multiple sclerosis (MS) and related disorders with coronavirus disease 2019 (COVID-19) illness.MethodsFrom March 16 to April 30, 2020, patients with MS or related disorders at NYU Langone MS Comprehensive Care Center were identified with laboratory-confirmed or suspected COVID-19. The diagnosis was established using a standardized questionnaire or by review of in-patient hospital records.ResultsWe identified 76 patients (55 with relapsing MS, of which 9 had pediatric onset; 17 with progressive MS; and 4 with related disorders). Thirty-seven underwent PCR testing and were confirmed positive. Of the entire group, 64 (84%) patients were on disease-modifying therapy (DMT) including anti-CD20 therapies (n = 34, 44.7%) and sphingosine-1-phosphate receptor modulators (n = 10, 13.5%). The most common COVID-19 symptoms were fever and cough, but 21.1% of patients had neurologic symptom recrudescence preceding or coinciding with the infection. A total of 18 (23.7%) were hospitalized; 8 (10.5%) had COVID-19 critical illness or related death. Features more common among those hospitalized or with critical illness or death were older age, presence of comorbidities, progressive disease, and a nonambulatory status. No DMT class was associated with an increased risk of hospitalization or fatal outcome.ConclusionsMost patients with MS with COVID-19 do not require hospitalization despite being on DMTs. Factors associated with critical illness were similar to the general at-risk patient population. DMT use did not emerge as a predictor of poor COVID-19 outcome in this preliminary sample.

APA, Harvard, Vancouver, ISO, and other styles

4

Chamani, Isaac J., David H. McCulloh, James A. Grifo, and Frederick L. Licciardi. "COVID-19 AND ART OUTCOMES." Fertility and Sterility 114, no. 3 (September 2020): e556. http://dx.doi.org/10.1016/j.fertnstert.2020.09.101.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Ramani, Chintan, Eric M. Davis, John S. Kim, J. Javier Provencio, Kyle B. Enfield, and Alex Kadl. "Post-ICU COVID-19 Outcomes." Chest 159, no. 1 (January 2021): 215–18. http://dx.doi.org/10.1016/j.chest.2020.08.2056.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

KHAMITOV, RUSTEM F., ALEXANDER V. ZHESTKOV, ALEXANDER A. VIZEL, and VASILY D. FEDOTOV. "COVID-19 OUTCOMES: DRUG TREATMENT OPTIONS." Bulletin of Contemporary Clinical Medicine 14, no. 5 (October 2021): 104–11. http://dx.doi.org/10.20969/vskm.2021.14(5).104-111.

Full text

Abstract:

Background. Since December 2019 there has been a rapid spread of the COVID-19 pandemic across most of the world. This has determined the enormous burden on the global economy. The burden of the new coronavirus infection is determined not only by the costs directly related to the treatment of the acute phase of the disease, but also by the successful rehabilitation of patients after COVID-19, risk reduction and timely management of adverse outcomes for optimal patient recovery. Aim. The aim of the study was to analyze the adverse outcomes of COVID-19 and to estimate the possibility of their correction and prevention. Material and methods. We analyzed the PubMed database for 2020–2021 using the keywords «COVID-19, pulmonary outcomes and treatment», as well as the online meetings of chief pulmonologists of the Volga Federal District (VFD) in April 2021, where we heard about the regional experience in prevention and correction of COVID-19 adverse outcomes. Results and discussion. More and more publications are appearing on the so-called «postdrome» after COVID-19. Postdrome problems are becoming increasingly important as more and more treated patients are discharged from hospitals. To date, there are already over 103 million COVID-19 survivors. In patients with severe or critical manifestations of the disease, widespread and progressive endothelial thrombosis with diffuse microvascular thrombosis is increasingly evident as the final stage of the proinflammatory cytokine storm. Adequate anticoagulant therapy primarily using heparins with direct antiviral activity, preventing venous thromboembolism, being used for pulmonary thrombosis, is relevant in the prevention of adverse outcomes. Many authors note long-lasting residual changes on lung CT after the acute phase of COVID-19. At the same time, unlike post-inflammatory pneumosclerosis in the outcome of bacterial pneumonias, these changes can often regress within 6–12 months after a viral infection. Along with the effects of optimal anticoagulant therapy in the prevention of adverse COVID-19 outcomes, the available literature discusses the possibility of different regimens of glucocorticosteroid therapy. At the expert council of pulmonology specialists of the Volga Federal District the regional experience of using a domestic drug bovgialuronidase azoximer (Longidase) with official indications for treatment of fibrosis was covered in the therapeutic complex of patients with severe forms of COVID-19. Conclusion. Accumulating the evidence base of different ways of prevention and correction of residual changes in COVID-19 patients, which significantly deteriorate patients’ ability to work as well as their quality of life, can be considered one of the main priorities of modern COVID-19 medicine.

APA, Harvard, Vancouver, ISO, and other styles

7

Nachon-Acosta, Andrea, Gustavo Martinez-Mier, Victor Flores-Gamboa, Octavio Avila-Mercado, Indira Morales Garcia, Carlos Yoldi-Aguirre, Irais Olivares-Garcia, and Maritza De la Paz-Roman. "Surgical Outcomes During COVID-19 Pandemic." Archives of Medical Research 52, no. 4 (May 2021): 434–42. http://dx.doi.org/10.1016/j.arcmed.2021.01.003.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Standl, Eberhard, and Oliver Schnell. "Heart failure outcomes and Covid-19." Diabetes Research and Clinical Practice 175 (May 2021): 108794. http://dx.doi.org/10.1016/j.diabres.2021.108794.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Akhtar, Zaki, Sumeet Sharma, Ahmed I. Elbatran, Lisa W. M. Leung, Christos Kontogiannis, Michael Spartalis, Alice Roberts, Abhay Bajpai, Zia Zuberi, and Mark M. Gallagher. "Medium-Term Outcomes in COVID-19." Journal of Clinical Medicine 11, no. 7 (April 5, 2022): 2033. http://dx.doi.org/10.3390/jcm11072033.

Full text

Abstract:

COVID-19 causes severe illness that results in morbidity and mortality. Electrocardiographic features, including QT prolongation, have been associated with poor acute outcomes; data on the medium-term outcomes remain scarce. This study evaluated the 1-year outcomes of patients who survived the acute COVID-19 infection. Methods and Materials: Data of the 159 patients who survived the COVID-19 illness during the first wave (1 March 2020–18 May 2020) were collected. Patient demographics, laboratory findings and electrocardiography data were evaluated. Patients who subsequently died within 1-year of the index illness were compared to those who remained well. Results: Of the 159 patients who had survived the index illness, 28 (17.6%) subsequently perished within 1-year. In comparison to the patients that were alive after 1-year, the deceased were older (68 vs. 83 years, p < 0.01) and equally male (60.4% vs. 53.6%, p = 0.68), with a similar proportion of hypertension (59.5% vs. 57.1%, p = 0.68), diabetes (25.2% vs. 39.2%, p = 0.096) and ischaemic heart disease (11.5% vs. 7.1%, p = 0.54). The QTc interval for the alive and deceased patients shortened by a similar degree from the illness to post-COVID (−26 ± 33.5 vs. −20.6 ± 30.04 milliseconds, p = 0.5); the post-COVID R-R interval was longer in the alive patients compared to the deceased (818.9 ± 169.3 vs. 761.1 ± 61.2 ms, p = 0.02). A multivariate Cox regression analysis revealed that age (HR1.098 [1.045–1.153], p < 0.01), diabetes (HR3.972 [1.47–10.8], p < 0.01) and the post-COVID R-R interval (HR0.993 [0.989–0.996], p < 0.01) were associated with 1-year mortality. Conclusions: The COVID-19-associated mortality risk extends to the post-COVID period. The QTc does recover following the acute illness and is not associated with outcomes; the R-R interval is a predictor of 1-year mortality.

APA, Harvard, Vancouver, ISO, and other styles

10

Tsay, Jun-Chieh J., and Robert L. Smith. "Covid-19 Outcomes Among US Veterans." Global Advances in Health and Medicine 11 (January 2022): 2164957X2211194. http://dx.doi.org/10.1177/2164957x221119474.

Full text

APA, Harvard, Vancouver, ISO, and other styles

11

Klein, Sabra L., Santosh Dhakal, Rebecca L. Ursin, Sharvari Deshpande, Kathryn Sandberg, and Franck Mauvais-Jarvis. "Biological sex impacts COVID-19 outcomes." PLOS Pathogens 16, no. 6 (June 22, 2020): e1008570. http://dx.doi.org/10.1371/journal.ppat.1008570.

Full text

APA, Harvard, Vancouver, ISO, and other styles

12

Lipworth, Brian, Rory Chan, and Chris R. Kuo. "Predicting Severe Outcomes in COVID-19." Journal of Allergy and Clinical Immunology: In Practice 8, no. 8 (September 2020): 2582–84. http://dx.doi.org/10.1016/j.jaip.2020.06.039.

Full text

APA, Harvard, Vancouver, ISO, and other styles

13

Alasia, D., O. Maduka, V. O. Oputa, N. Orazulike, J. Otokwala, N. Osemwegie, C. Ozah, et al. "COVID-19 and Pregnancy:." West Africa Journal of Medicine 38, no. 11 (November 30, 2021): 1036–41. http://dx.doi.org/10.55891/wajm.v38i11.11.

Full text

Abstract:

Background: It is known that pregnant women are more susceptible to viral infectious diseases, with an attendant risk of adverse foetal and maternal outcomes. The objective of this descriptive study is to evaluate the epidemiologic and clinical pattern, as well as the obstetric and COVID-19 outcome among pregnant women seen at a tertiary hospital in Southern, Nigeria. Methods: This was a descriptive prospective study of all pregnant women seen and diagnosed with COVID-19 based on positive RT-PCR for SARS-COV-2, at the University of Port Harcourt Teaching Hospital, Port Harcourt, Rivers State, Nigeria from March 2020 to August 2020. Results: Seven (5.2%) pregnant patients were diagnosed with COVID-19 out of 134 patients. The common presenting symptoms were fever 4(57.1%), Productive cough 3 (42.9%), shortness of breath 3 (42.9%), myalgia 3 (42.9%), rhinorrhoea 3 (42.9%), and anosmia 3 (42.9%). The majority (85.7%) of patients were in the second and third trimesters at diagnosis. All deliveries occurred at term, with a mean gestational age of 38±0.82 weeks. Four patients (57.1%) had caesarean section (CS) deliveries for obstetric indications. No adverse outcomes were recorded for mothers and babies with birth weight ranging from 2.5 to 3.5 Kg. No case fatality was recorded. Conclusion: In this study, pregnant women with COVID-19 did not have adverse maternal and foetal outcome. The pattern of symptoms and the presence of severe disease also did not differ from what is observed in the general non-pregnant population. The impact of COVID-19 on pregnancy is less severe when compared to other high consequence viral infectious diseases. Keywords: COVID-19; Obstetrics; Pregnancy; SARS-CoV-2.

APA, Harvard, Vancouver, ISO, and other styles

14

Bologheanu, Răzvan, Mathias Maleczek, Daniel Laxar, and Oliver Kimberger. "Outcomes of non-COVID-19 critically ill patients during the COVID-19 pandemic." Wiener klinische Wochenschrift 133, no. 17-18 (April 19, 2021): 942–50. http://dx.doi.org/10.1007/s00508-021-01857-4.

Full text

Abstract:

Summary Background Coronavirus disease 2019 (COVID-19) disrupts routine care and alters treatment pathways in every medical specialty, including intensive care medicine, which has been at the core of the pandemic response. The impact of the pandemic is inevitably not limited to patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and their outcomes; however, the impact of COVID-19 on intensive care has not yet been analyzed. Methods The objective of this propensity score-matched study was to compare the clinical outcomes of non-COVID-19 critically ill patients with the outcomes of prepandemic patients. Critically ill, non-COVID-19 patients admitted to the intensive care unit (ICU) during the first wave of the pandemic were matched with patients admitted in the previous year. Mortality, length of stay, and rate of readmission were compared between the two groups after matching. Results A total of 211 critically ill SARS-CoV‑2 negative patients admitted between 13 March 2020 and 16 May 2020 were matched to 211 controls, selected from a matching pool of 1421 eligible patients admitted to the ICU in 2019. After matching, the outcomes were not significantly different between the two groups: ICU mortality was 5.2% in 2019 and 8.5% in 2020, p = 0.248, while intrahospital mortality was 10.9% in 2019 and 14.2% in 2020, p = 0.378. The median ICU length of stay was similar in 2019: 4 days (IQR 2–6) compared to 2020: 4 days (IQR 2–7), p = 0.196. The rate of ICU readmission was 15.6% in 2019 and 10.9% in 2020, p = 0.344. Conclusion In this retrospective single center study, mortality, ICU length of stay, and rate of ICU readmission did not differ significantly between patients admitted to the ICU during the implementation of hospital-wide COVID-19 contingency planning and patients admitted to the ICU before the pandemic.

APA, Harvard, Vancouver, ISO, and other styles

15

Beatriz Cruz, Angela, Jennifer LeRose, and Teena Chopra. "Comparison of Outcomes in Candidemia Between COVID-19 and Non–COVID-19 Patients." Antimicrobial Stewardship & Healthcare Epidemiology 1, S1 (July 2021): s58. http://dx.doi.org/10.1017/ash.2021.112.

Full text

Abstract:

Background: Fungemia is associated with high rates of morbidity, mortality, and increase in length of hospital stay. Several studies have recognized increased rates of candidemia since the COVID-19 pandemic. Methods: Patients with candidemia during January through May 2020 were identified through Theradoc. Patient demographics, comorbidities, hospital management, and microbiology were extracted by medical chart review. Patients were divided into cohorts based on COVID-19 status. The Fisher exact and Satterthwaite tests were used for analyses of categorical and continuous variables, respectively. Results: Overall, 31 patients developed candidemia and 12 (38.7%) patients tested SARS-CoV-2 positive. Candida glabrata was the most prevalent causative organism in both groups. On average, COVID-19 patients developed fungemia 12.1 days from admission, compared to 17.8 days in the COVID-19 negative or untested cohort (P = .340). Additionally, COVID-19 patients with a fungemia coinfection were significantly more likely to expire; 10 COVID-19 patients (83.3%) died, compared to 7 (36.8%) in the COVID-19–negative or untested cohort (P = .025). The cohorts did not demonstrate statistically significant differences in terms of demographic, comorbidities, hospital management, or coinfections. Conclusions: The prevalence of fungemia in COVID-19 patients is significantly greater than historically reported figures. Known risk factors for candidemia, such as use of corticosteroid, use of central venous catheters, and prolonged ICU length of stay were higher in the SARS-CoV-2–positive cohort in this period, which likely contributed to increased fungemia rates, as these factors are also more pronounced in those with COVID-19. Patients who developed candidemia in the COVID-19 cohort had poorer outcomes than those who were SARS-CoV-2 negative or were untested. Further investigation should be conducted in larger studies.Funding: NoDisclosures: None

APA, Harvard, Vancouver, ISO, and other styles

16

Rokadiya, S., E. Gil, C. Stubbs, D. Bell, and R. Herbert. "COVID-19: Outcomes of patients with confirmed COVID-19 re-admitted to hospital." Journal of Infection 81, no. 3 (September 2020): e18-e19. http://dx.doi.org/10.1016/j.jinf.2020.07.007.

Full text

APA, Harvard, Vancouver, ISO, and other styles

17

Roberts, F., K. Birmingham, L. Darlison, K. Hertzberg, K. Chapman, J. Krampikowski, D. Bunden, L. King, E. Tebbutt, and E. Potter. "142 Improving Functional Outcomes During Covid-19 for Both COVID-19 and Non COVID-19 Positive Older Adults Through the Introduction." Age and Ageing 50, Supplement_1 (March 2021): i12—i42. http://dx.doi.org/10.1093/ageing/afab030.103.

Full text

Abstract:

Abstract Purpose To improve the functional outcomes of older adults presenting to the Health and Ageing wards during the COVID-19 pandemic through a focussed rehabilitation list. The intended benefits to the older adult and service were for: 1. Daily rehabilitation input for older adults. 2. Older adults to spend less time immobile. 3. Ongoing rehabilitation intervention while awaiting medical clearance for discharge. 4. Increased staff satisfaction 5. Better outcomes on discharge. 6. Rehabilitation ethos on the Health and Ageing wards. Methods The quality improvement project was carried out using the Plan, Do, Study, Act (PDSA) cycle. Three iterative PDSA cycles were carried out over the course of the project to deliver proactive interventions as a result of analysis of baseline data and stakeholder involvement. These interventions were aimed at developing communication around the rehabilitation list within the team and sustainability of this list. Results The project resulted in better functional outcomes for older adults and increased staff morale. Between May 2020–June 2020, a total of 56 patients were seen on the rehabilitation list, with 84% of these patients seeing improvements in their Elderly Mobility Scores (EMS). 27% of patients on the rehabilitation list saw a change to their initial discharge plan, either needing reduced packages of care or reduced need for ongoing rehabilitation in an external setting. Conclusions The quality improvement project found that with focussed rehabilitation older adult inpatients with or without COVID-19 can make significant functional gains. These gains have wider effects on their outcomes on discharge and also for the service through increased morale and job satisfaction. Due to demand and capacity issues in the acute setting, older adults who would often benefit from ongoing input are not always reviewed regularly. This project demonstrates that with focussed rehabilitation older adults can improve and achieve better functional outcomes.

APA, Harvard, Vancouver, ISO, and other styles

18

Ntounis, Thomas, Ioannis Prokopakis, Antonios Koutras, Zacharias Fasoulakis, Savia Pittokopitou, Asimina Valsamaki, Athanasios Chionis, et al. "Pregnancy and COVID-19." Journal of Clinical Medicine 11, no. 22 (November 9, 2022): 6645. http://dx.doi.org/10.3390/jcm11226645.

Full text

Abstract:

Evidence indicates that SARS-CoV-2 infection increases the likelihood of adverse pregnancy outcomes. Modifications in the circulatory, pulmonary, hormonal, and immunological pathways induced by pregnancy render pregnant women as a high-risk group. A growing body of research shows that SARS-CoV-2 infection during pregnancy is connected to a number of maternal complications, including pneumonia and intensive care unit (ICU) hospitalization. Miscarriages, stillbirth, preterm labor, as well as pre-eclampsia and intrauterine growth restriction are also among the most often documented fetal implications, particularly among expecting women who have significant COVID-19 symptoms, often affecting the timing and route of delivery. Thus, prevention of infection and pharmacological treatment options should aim to minimize the aforementioned risks and ameliorate maternal, obstetric and fetal/neonatal outcomes.

APA, Harvard, Vancouver, ISO, and other styles

19

Padalia, Kishan, Patrick J. O’Hayer, Elizabeth Anderson, Michael Pan, Tariq Azam, Husam Shadid, Hannah Berlin, et al. "OBESITY, INFLAMMATION, AND OUTCOMES IN COVID-19." Journal of the American College of Cardiology 77, no. 18 (May 2021): 3032. http://dx.doi.org/10.1016/s0735-1097(21)04387-4.

Full text

APA, Harvard, Vancouver, ISO, and other styles

20

M Khamiss, Ahmed, Magdy El-Dahshan, Fathy El-Ghamery, Mohamed Aggag, Alaa Hashim, and Ahmed Eliwa. "OUTCOMES OF COVID-19 IN EGYPTIAN PATIENTS." Al-Azhar Medical Journal 50, no. 1 (January 1, 2021): 765–82. http://dx.doi.org/10.21608/amj.2021.139876.

Full text

APA, Harvard, Vancouver, ISO, and other styles

21

Pakhchanian, Haig, Rahul Raiker, Amrita Mukherjee, Ahmad Khan, Shailendra Singh, and Arka Chatterjee. "Outcomes of COVID-19 in CKD Patients." Clinical Journal of the American Society of Nephrology 16, no. 5 (February 8, 2021): 785–86. http://dx.doi.org/10.2215/cjn.13820820.

Full text

APA, Harvard, Vancouver, ISO, and other styles

22

Voloshin, Dmitriy, Zoya Rumyantseva, Il'ya Glazkov, Anna Sulima, Natal'ya Reznichenko, and Viktoriya Moskvina. "PERINATAL OUTCOMES IN WOMEN WITH COVID-19." Ulyanovsk Medico-biological Journal, no. 1 (April 20, 2022): 49–55. http://dx.doi.org/10.34014/2227-1848-2022-1-49-55.

Full text

Abstract:

COVID-19 pathogenesis has not been fully understood yet. However, the virus is known to enter the epithelial cells of the upper respiratory and gastrointestinal tracts, activating S-protein by angiotensin-converting enzyme 2. This process can significantly affect the pregnancy, childbirth and postpartum period. The aim of the study is to analyze the impact of COVID-19 on pregnancy course and outcomes. Materials and Methods. The authors retrospectively analyzed case histories and surgical protocols of 67 pregnant women with confirmed and suspected COVID-19, and neonatal records of 59 newborns who were in contact with COVID-19 patients. Results. Childbirth due to antenatal fetal death occurred in 13.4 % of cases, preterm births were observed in 15.5 %. Besides, 15.2 % of children were born prematurely by gestational age (the average rate for the Russian Federation is 8–11 %); invasive artificial lung ventilation was required in 3.4 % of newborns; primary neonatal resuscitation was performed in 18.6 % of cases. PCR examination of oropharyngeal swabs for SARS-CoV-2 detection did not confirm the presence of COVID-19 causative agents. Neonatal jaundice was diagnosed in 83.1 % of cases (the average rate for the Russian Federation is 60 %). Phototherapy (serum bilirubin >220 µmol/l, transcutaneous bilirubin index >200, Kramer scale score 3–4) was required in 77.5 % of such children (the average rate for Russia is 40–50 %). Conclusion. The conducted study indicates a significant impact of COVID-19 on pregnancy course and outcomes: the risks of preterm birth, antenatal fetus death, and the need for primary neonatal resuscitation also increase.

APA, Harvard, Vancouver, ISO, and other styles

23

Tejpal, Astha, Eugenia Gianos, Jane Cerise, Jamie S. Hirsch, Stacey Rosen, Nina Kohn, Martin Lesser, et al. "Sex-Based Differences in COVID-19 Outcomes." Journal of Women's Health 30, no. 4 (April 1, 2021): 492–501. http://dx.doi.org/10.1089/jwh.2020.8974.

Full text

APA, Harvard, Vancouver, ISO, and other styles

24

Sam, Shem Otoi, Ganesh P. Pokhariyal, and Khama Rogo. "Antecedents of patients Covid-19 management outcomes." International Journal of Statistics and Applied Mathematics 6, no. 5 (September 1, 2021): 109–17. http://dx.doi.org/10.22271/maths.2021.v6.i5b.730.

Full text

APA, Harvard, Vancouver, ISO, and other styles

25

Das, V. K., Kaveri Pandya, Bincy Mathew, and Anjali Prajapati. "Mystery of perinatal outcomes by COVID-19." International Journal Of Community Medicine And Public Health 8, no. 8 (July 27, 2021): 3994. http://dx.doi.org/10.18203/2394-6040.ijcmph20213034.

Full text

Abstract:

Background: The coronavirus disease is continuously affecting the lives of all people and it has grown into a pandemic. Understanding the impact of COVID-19 on pregnancy in terms of morbidity, mortality as well as perinatal-maternal and foetal outcomes is essential to propose strategies for prevention and infection control. In this study, an attempt has been made to assess the impact of COVID-19 on perinatal outcomes.Methods: It was a retrospective analytical study. The case-files of 47 antenatal mothers who were RT-PCR positive & delivered during the course of treatment were taken for the study.Results: Out of all samples, 91.49% were asymptomatic, 10.63% had pregnancy induced hypertension (PIH) as comorbidity, 88.10% had anaemia, 40.43% had WBC count more than 10,000/mm3. 97.87 % of the samples recovered from COVID-19 with routine obstetrical management and only one case was kept on BIPAP support. Perinatal complications like preterm deliveries (27.66%), foetal distress (27.66%), NRNST (19.15%), PROM (4.26%), decreased foetal movement (2.13 %), LBW (6.38%), APGAR<7 at 5 min (15.55%), still birth (4.26%), NICU admission (31.11%), neonatal death (2.13%) were identified. 68.89% neonates were breastfed. The RT-PCR of all neonates came negative on first day of delivery which indicates that there was no vertical transmission. In this study, the results show that the perinatal outcomes are mildly affected by COVID-19.Conclusions: Although COVID-19 doesn’t directly affect perinatal outcomes, it has indirect adverse effects on MCH services. Hence, emergency obstetric and neonatal care is an essential service to be continued with awareness of people while maintaining social distancing and personal hygiene.

APA, Harvard, Vancouver, ISO, and other styles

26

Alqahtani, Jaber S., Saeed M. Alghamdi, Abdulelah M. Aldhahir, Malik Althobiani, Reynie Purnama Raya, and Tope Oyelade. "Thoracic imaging outcomes in COVID-19 survivors." World Journal of Radiology 13, no. 6 (June 28, 2021): 149–56. http://dx.doi.org/10.4329/wjr.v13.i6.149.

Full text

APA, Harvard, Vancouver, ISO, and other styles

27

Chamani, I. J., M. S. Chung, R. A. Cochran, W. E. Gibbons, and L. J. McKenzie. "ART OUTCOMES DURING THE COVID-19 PANDEMIC." Fertility and Sterility 116, no. 1 (July 2021): e8-e9. http://dx.doi.org/10.1016/j.fertnstert.2021.05.014.

Full text

APA, Harvard, Vancouver, ISO, and other styles

28

Xie, Yan, Evan Xu, Benjamin Bowe, and Ziyad Al-Aly. "Long-term cardiovascular outcomes of COVID-19." Nature Medicine 28, no. 3 (February 7, 2022): 583–90. http://dx.doi.org/10.1038/s41591-022-01689-3.

Full text

Abstract:

AbstractThe cardiovascular complications of acute coronavirus disease 2019 (COVID-19) are well described, but the post-acute cardiovascular manifestations of COVID-19 have not yet been comprehensively characterized. Here we used national healthcare databases from the US Department of Veterans Affairs to build a cohort of 153,760 individuals with COVID-19, as well as two sets of control cohorts with 5,637,647 (contemporary controls) and 5,859,411 (historical controls) individuals, to estimate risks and 1-year burdens of a set of pre-specified incident cardiovascular outcomes. We show that, beyond the first 30 d after infection, individuals with COVID-19 are at increased risk of incident cardiovascular disease spanning several categories, including cerebrovascular disorders, dysrhythmias, ischemic and non-ischemic heart disease, pericarditis, myocarditis, heart failure and thromboembolic disease. These risks and burdens were evident even among individuals who were not hospitalized during the acute phase of the infection and increased in a graded fashion according to the care setting during the acute phase (non-hospitalized, hospitalized and admitted to intensive care). Our results provide evidence that the risk and 1-year burden of cardiovascular disease in survivors of acute COVID-19 are substantial. Care pathways of those surviving the acute episode of COVID-19 should include attention to cardiovascular health and disease.

APA, Harvard, Vancouver, ISO, and other styles

29

Valle, Ana, and Shereen N. Mahmood. "COVID-19 Outcomes in Idiopathic Inflammatory Myopathies." JCR: Journal of Clinical Rheumatology 28, no. 3 (January 24, 2022): 174–76. http://dx.doi.org/10.1097/rhu.0000000000001822.

Full text

APA, Harvard, Vancouver, ISO, and other styles

30

Chamani, Isaac J., James Grifo, Monica S. Chung, Laurie J. McKenzie, David H. McCulloh, William E. Gibbons, and Frederick L. Licciarid. "ART outcomes during the COVID-19 pandemic." Clinical and Experimental Obstetrics & Gynecology 49, no. 4 (April 2, 2022): 82. http://dx.doi.org/10.31083/j.ceog4904082.

Full text

APA, Harvard, Vancouver, ISO, and other styles

31

Doyle, Margaret F. "Central nervous system outcomes of COVID-19." Translational Research 241 (March 2022): 41–51. http://dx.doi.org/10.1016/j.trsl.2021.09.002.

Full text

APA, Harvard, Vancouver, ISO, and other styles

32

Chamani, Isaac J., David H. McCulloh, Frederick L. Licciardi, and James A. Grifo. "FET OUTCOMES DURING THE COVID-19 PANDEMIC." Fertility and Sterility 116, no. 3 (September 2021): e294. http://dx.doi.org/10.1016/j.fertnstert.2021.07.791.

Full text

APA, Harvard, Vancouver, ISO, and other styles

33

Ochoa, Lizbeth Burgos, Meredith Brockway, Sarah J. Stock, and Jasper V. Been. "COVID-19 and maternal and perinatal outcomes." Lancet Global Health 9, no. 8 (August 2021): e1063-e1064. http://dx.doi.org/10.1016/s2214-109x(21)00295-3.

Full text

APA, Harvard, Vancouver, ISO, and other styles

34

Leisher, Susannah Hopkins. "COVID-19 and maternal and perinatal outcomes." Lancet Global Health 9, no. 8 (August 2021): e1061. http://dx.doi.org/10.1016/s2214-109x(21)00296-5.

Full text

APA, Harvard, Vancouver, ISO, and other styles

35

Calvert, Clara, Jeeva John, Farirai P. Nzvere, and Wendy J. Graham. "COVID-19 and maternal and perinatal outcomes." Lancet Global Health 9, no. 8 (August 2021): e1062. http://dx.doi.org/10.1016/s2214-109x(21)00302-8.

Full text

APA, Harvard, Vancouver, ISO, and other styles

36

Aranda, Zeus, Isabel R. Fulcher, Bethany Hedt-Gauthier, Jean Claude Mugunga, and Thierry Binde. "COVID-19 and maternal and perinatal outcomes." Lancet Global Health 9, no. 8 (August 2021): e1065. http://dx.doi.org/10.1016/s2214-109x(21)00297-7.

Full text

APA, Harvard, Vancouver, ISO, and other styles

37

Fonseca, Luis Miguel, and Américo Lopes Azevedo. "COVID- 19: outcomes for Global Supply Chains." Management & Marketing. Challenges for the Knowledge Society 15, s1 (October 1, 2020): 424–38. http://dx.doi.org/10.2478/mmcks-2020-0025.

Full text

Abstract:

AbstractThe COVID-19 crisis exposed the vulnerability and poor resilience of the global supply chains. The objective of this research is to reflect on the possible impacts of the Coronavirus crisis in the global supply chains and provide some recommendations to overcome the present situation, offering suggestions for future research: (1) What are the contingency factors affecting Supply Chains in the complex COVID-19 operating environment? (2) How do these factors affect post-COVID-19 operating performance? After a contextualization of the COVID-19 pandemic crisis and its impacts, theoretical background on Supply Chains and Supply Chain Management are presented, and a summary of the main scenarios for the post-COVID-19 crisis are discussed. The propositions regarding the contingency factors and their impact on the Supply Chain operating performance in post-COVID-19 suggest that successful companies will focus on creating a new kind of operational performance and minimize risks. To that end, companies will aim to improve their operations’ resilience (ability to resist, hold on, and recover from shocks) and accelerate the end-to-end digital transformation. Consumers will have to adapt to the contact-free economy, less low-cost supply chains, and put additional emphasis on service levels. Governments will reinforce the focus in the health sector supply chain and increase spending in the health and social care sectors. Furthermore, the longer, the more concentrated, the less transparent, and the more price sensitivity is the supply chain, the more challenging the adaptation to the new pos pandemic realities. Suggestions for future research are also provided.

APA, Harvard, Vancouver, ISO, and other styles

38

Nair, Vinay, Nicholas Jandovitz, Kenar D. Jhaveri, and Ernesto Molmenti. "COVID-19 and solid organ transplant outcomes." Nephrology Dialysis Transplantation 35, no. 8 (August 1, 2020): 1444–46. http://dx.doi.org/10.1093/ndt/gfaa207.

Full text

APA, Harvard, Vancouver, ISO, and other styles

39

Chao, Tiffany N., Sean P. Harbison, Benjamin M. Braslow, Christoph T. Hutchinson, Karthik Rajasekaran, Beatrice C. Go, Ellen A. Paul, et al. "Outcomes After Tracheostomy in COVID-19 Patients." Annals of Surgery 272, no. 3 (June 11, 2020): e181-e186. http://dx.doi.org/10.1097/sla.0000000000004166.

Full text

APA, Harvard, Vancouver, ISO, and other styles

40

Murray, Michael F., Eimear E. Kenny, Marylyn D. Ritchie, Daniel J. Rader, Allen E. Bale, Monica A. Giovanni, and Noura S. Abul-Husn. "COVID-19 outcomes and the human genome." Genetics in Medicine 22, no. 7 (May 12, 2020): 1175–77. http://dx.doi.org/10.1038/s41436-020-0832-3.

Full text

APA, Harvard, Vancouver, ISO, and other styles

41

Berger, Mette M. "Nutrition Status Affects COVID‐19 Patient Outcomes." Journal of Parenteral and Enteral Nutrition 44, no. 7 (July 15, 2020): 1166–67. http://dx.doi.org/10.1002/jpen.1954.

Full text

APA, Harvard, Vancouver, ISO, and other styles

42

Strope, Jonathan D., Cindy H. Chau, PharmD, and William D. Figg. "TMPRSS2: Potential Biomarker for COVID‐19 Outcomes." Journal of Clinical Pharmacology 60, no. 7 (May 21, 2020): 801–7. http://dx.doi.org/10.1002/jcph.1641.

Full text

APA, Harvard, Vancouver, ISO, and other styles

43

Elkhouly, Mohamed, and Ahmed Fouad. "Tube Thoracostomy Outcomes in COVID-19 Patients." Egyptian Journal of Hospital Medicine 89, no. 2 (October 1, 2022): 6214–17. http://dx.doi.org/10.21608/ejhm.2022.268117.

Full text

APA, Harvard, Vancouver, ISO, and other styles

44

Siddiq, Ahmed. "Cytokine flames of COVID-19." Archives of Medical Case Reports and Case Study 3, no. 2 (September 16, 2020): 01–02. http://dx.doi.org/10.31579/2692-9392/014.

Full text

Abstract:

COVID-19 (Corona Virus Disease 2019) is leaving clinicians and scientists baffled with its clinical presentation spectrum ranging from completely asymptomatic patients with complete and smooth recovery to fatal outcomes in apparently healthy, young and immunocompetent individuals within days even with the support of most advanced healthcare staff and logistic facilities

APA, Harvard, Vancouver, ISO, and other styles

45

Soares, Rafael. "Acute Arterial Occlusions in Patients with COVID-19: Results and Outcomes." Clinical Cardiology and Cardiovascular Interventions 4, no. 1 (January 6, 2021): 01–08. http://dx.doi.org/10.31579/2641-0419/120.

Full text

Abstract:

In this paper, we aimed to describe a case series report of four patients that were admitted in the emergency room of our vascular and endovascular surgery department with acute arterial occlusion after a diagnosis of Covid-19 infection. The first patient was a male, 50 years, tobacco user, with arterial systemic hypertension and COVID-19 positive that was admitted with an acute arterial occlusion Rutherford IIb in the left lower limb. He was submitted to an arterial thromboembolectomy with Fogarty catheter and had a satisfactory evolution. CASE 2 was a female, 63 years, with arterial systemic hypertension, diabetes, esquizophrenia, that was admitted with acute limb ischemia (ALI) Rutherford III in the upper left limb. Despite attempts do revascularize the upper limb, the patient evolved with a hand amputation. CASE 3 was a Male patient, 49 years, HIV positive, diabetic with previous debridement in both feet due to diabetic foot infection, tobacco user and Rutherford IIb ALI in the right lower limb..The patient was submitted to an arterial thromboembolectomy with Fogarty catheter, however presented with fasciotomy infection and another post-operative complications that led him to die. Finally, CASE 4 was a female patient, 49 years, diabetic, admitted with COVID-19 infection that presented ALI during hospitalization on the right lower limb. She was submitted to proper thromboembolectomy, with a satisfactory evolution and limb salvage. COVID-19 pandemic crisis is a challenging situation that has increased the number of acute arterial thrombosis and embolism urgencies and emergencies surgeries in the vascular world. The four patients related in this paper bring valuable information regarding the impact of COVID-19 on micro and macrovascular system.

APA, Harvard, Vancouver, ISO, and other styles

46

Beach, Scott R., Richard Schulz, Heidi Donovan, and Ann-Marie Rosland. "Family Caregiving During the COVID-19 Pandemic." Gerontologist 61, no. 5 (April 13, 2021): 650–60. http://dx.doi.org/10.1093/geront/gnab049.

Full text

Abstract:

Abstract Background and Objectives The coronavirus disease 2019 (COVID-19) pandemic has negatively affected persons with existing chronic health conditions. The pandemic also has the potential to exacerbate the stresses of family caregiving. We compare family caregivers with noncaregivers on physical, psychosocial, and financial well-being outcomes during the pandemic and determine family caregivers most at risk for adverse outcomes. Research Design and Methods We conducted a cross-sectional online survey of 576 family caregivers and 2,933 noncaregivers from April to May 2020 in Pittsburgh, PA region with a national supplement. Outcome measures included concurrent anxiety, depression, fatigue, sleep disturbance, social participation, and financial well-being and perceived changes due to COVID-19 (loneliness, financial well-being, food security). We also measured sociodemographic, caregiving contextual variables, and COVID-19-related caregiver stressors (COVID Caregiver Risk Index). Results Controlling for sociodemographics, family caregivers reported higher anxiety, depression, fatigue, sleep disturbance, lower social participation, lower financial well-being, increased food insecurity (all p < .01), and increased financial worries (p = .01). Caregivers who reported more COVID-19-related caregiver stressors and disruptions reported more adverse outcomes (all p < .01). In addition, caregivers who were female, younger, lower income, providing both personal/medical care, and providing care for cognitive/behavioral/emotional problems reported more adverse outcomes. Discussion and Implications Challenges of caregiving are exacerbated by the COVID-19 pandemic. Family caregivers reported increased duties, burdens, and resulting adverse health, psychosocial, and financial outcomes. Results were generally consistent with caregiver stress–health process models. Family caregivers should receive increased support during this serious public health crisis.

APA, Harvard, Vancouver, ISO, and other styles

47

Mcloughlin, Benjamin C., Amy Miles, Thomas E. Webb, Paul Knopp, Clodagh Eyres, Ambra Fabbri, Fiona Humphries, and Daniel Davis. "Functional and cognitive outcomes after COVID-19 delirium." European Geriatric Medicine 11, no. 5 (July 14, 2020): 857–62. http://dx.doi.org/10.1007/s41999-020-00353-8.

Full text

Abstract:

Abstract Purpose To ascertain delirium prevalence and outcomes in COVID-19. Methods We conducted a point-prevalence study in a cohort of COVID-19 inpatients at University College Hospital. Delirium was defined by DSM-IV criteria. The primary outcome was all-cause mortality at 4 weeks; secondary outcomes were physical and cognitive function. Results In 71 patients (mean age 61, 75% men), 31 (42%) had delirium, of which only 12 (39%) had been recognised by the clinical team. At 4 weeks, 20 (28%) had died, 26 (36%) were interviewed by telephone and 21 (30%) remained as inpatients. Physical function was substantially worse in people after delirium − 50 out of 166 points (95% CI − 83 to − 17, p = 0.01). Mean cognitive scores at follow-up were similar and delirium was not associated with mortality in this sample. Conclusions Our findings indicate that delirium is common, yet under-recognised. Delirium is associated with functional impairments in the medium term.

APA, Harvard, Vancouver, ISO, and other styles

48

Nanda, Sanjeev, Loren Toussaint, Ann Vincent, Karen M. Fischer, Ryan Hurt, Darrell R. Schroeder, Audry S. Chacin Suarez, et al. "A Midwest COVID-19 Cohort for the Evaluation of Multimorbidity and Adverse Outcomes from COVID-19." Journal of Primary Care & Community Health 12 (January 2021): 215013272110109. http://dx.doi.org/10.1177/21501327211010991.

Full text

Abstract:

Objective To describe the process and outcome of creating a patient cohort in the early stages of the COVID-19 pandemic in order to better understand the process of and predict the outcomes of COVID-19. Patients and Methods A total of 1169 adults aged 18 years of age or older who tested positive in Mayo Clinic Rochester or the Mayo Clinic Midwest Health System between January 1 and May 23 of 2020. Results Patients were on average 43.9 years of age and 50.7% were female. Most patients were white (69.0%), and Blacks (23.4%) and Asians (5.8%) were also represented in larger numbers. Hispanics represented 16.3% of the sample. Just under half of patients were married (48.4%). Common comorbid conditions included: cardiovascular diseases (25.1%), dyslipidemia (16.0%), diabetes mellitus (11.2%), chronic obstructive pulmonary disease (6.6%), asthma (7.5%), and cancer (5.1%). All other comorbid conditions were less the 5% in prevalence. Data on 3 comorbidity indices are also available including the: DHHS multi-morbidity score, Charlson Comorbidity Index, and Mayo Clinic COVID-19 Risk Factor Score. Conclusion In addition to managing the ever raging pandemic and growing death rates, it is equally important that we develop adequate resources for the investigation and understanding of COVID-19-related predictors and outcomes.

APA, Harvard, Vancouver, ISO, and other styles

49

Khang, Ah Reum. "Glucose-Lowering Agents and COVID-19." Journal of Korean Diabetes 23, no. 1 (March 31, 2022): 1–6. http://dx.doi.org/10.4093/jkd.2022.23.1.1.

Full text

Abstract:

Coronavirus disease 2019 (COVID-19) is continuing to spread around the world despite the introduction of vaccines. Individuals with diabetes have been reported to have more severe clinical outcomes of COVID-19 infection. As there is potential that glucose-lowering agents can influence the clinical outcomes in diabetic patients with COVID-19, a number of studies are ongoing to explore the differences in clinical outcomes related to glucose-lowering agents. In this article, I summarize the published research on the relationship between glucose-lowering agents and clinical outcomes of diabetic patients with COVID-19 and suggest clinical consideration for usage of glucose-lowering agents.

APA, Harvard, Vancouver, ISO, and other styles

50

Petrova, N. N., V. E. Pashkovskiy, M. S. Sivashova, A. N. Gvozdetsky, and G. A. Prokopovich. "Impact of mental disorders on COVID-19 outcomes." Neurology, Neuropsychiatry, Psychosomatics 13, no. 5 (October 17, 2021): 40–47. http://dx.doi.org/10.14412/2074-2711-2021-5-40-47.

Full text

Abstract:

Objective: to analyze clinical and follow-up indicators in patients with mental disorders and COVID-19 and to identify on their basis predictors of poor outcomes associated with mental state.Patients and methods. We conducted a prospective study in a multidisciplinary hospital. The severity of coronavirus infection was determined according to the temporary guidelines. Data collection was carried out using a patient chart consisting of 109 variables. Predictors of poor outcomes were determined using predictive models (logit regression, Cox model). The study included 97 patients: 41 men (42.3%) and 56 (57.7%) women, mean age – 62.3±15.3 years. 26 patients died; 71 patients recovered.Results and discussion. The death occurred on 11.5 day. The mental state of these patients was severe, with a predominance of delirium cases. With increasing age, the probability of non-lethal outcome decreases [hazard ratio (HR) 1.03; 95% confidence interval (CI) 1.00–1.06; p=0.037]. The risk of death increased by 1.03 (p=0.037) for each year of life. An improvement in the mental state of patients during psychotropic therapy is associated with an 11.11-fold decrease in the risk of poor outcome of coronavirus infection (HR 0.09; 95% CI 0.01–0.76; p=0.027). Delirium is a predictor of low patient survival, especially in prolonged hospitalizations (HR 4.55; 95% CI 1.66–12.48; p=0.003). The severity of coronavirus infection makes the greatest contribution to the poor outcome: the risk of death increases by 33.17 times (CR 33.17; 95% CI 4.01–274.65; p<0.001). The severity of the mental disorder had a greater impact on the risk of death compared with age, increasing it by 4.55 times (p=0.003).Conclusion. We found significant differences between the groups of deceased and surviving patients with COVID-19 concerning the variables related to certain mental disorders, their severity and dynamics, and the severity of coronavirus infection. In addition, the age of the patients had a significant impact on the prognosis of COVID-19. The results reflect the special prognostic significance of delirium in the structure of mental disorders developing in patients with coronavirus infection.

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!